Eloctate

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
012320142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
: The aim of this study was to compare the hemostatic efficacy of recombinant factor VIII Fc (rFVIIIFc) (Eloctate) and Advate by… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy… (More)
Is this relevant?
2016
2016
To the Editor, Inhibitor formation is a serious complication of haemophilia treatment, occurring in approximately 28% of those… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2015
Review
2015
  • The Medical letter on drugs and therapeutics
  • 2015
Eloctate, a recombinant factor VIII Fc fusion protein with an extended half-life, was effective in preventing and controlling… (More)
Is this relevant?
Review
2015
Review
2015
  • Anne Tiede
  • Journal of thrombosis and haemostasis : JTH
  • 2015
Prophylactic infusion of factor VIII (FVIII) prevents joint bleeding and other hemorrhages in patients with hemophilia A… (More)
Is this relevant?
2014
2014
Inhibitor formation is among the most serious complications of hemophilia treatment. With the US FDA licensure of the novel long… (More)
Is this relevant?
Review
2014
Review
2014
  • 2014
NEW DRUG APPROVALS Dalvance for Skin Infections The FDA has approved dalbavancin (Dalvance, Durata Therapeutics) to treat adults… (More)
Is this relevant?